RNA signature points to whether patients will respond to aspirin, study finds

07/8/2013 | Charlotte Observer (N.C.), The

Between 10% and 15% of Americans who take a daily aspirin to prevent cardiovascular events are resistant to the drug and may not substantially benefit from the regime, according to a Duke University study reported in the Journal of the American College of Cardiology. Researchers devised an RNA blood test to identify how effective aspirin treatment was likely to be. It's not clear whether higher doses of aspirin would help, researcher Dr. Geoffrey S. Ginsburg said, calling the study "another step in more personalized medicine."

View Full Article in:

Charlotte Observer (N.C.), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Associate Manager, Regulatory Affairs
Stryker
Mahwah, NJ
Associate General Counsel
Patient-Centered Outcomes Research Institute
Washington, D.C , DC
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC